Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy

Meiwan Chen, Xingzhi Zhou, Ruie Chen, Junlin Wang, Richard D. Ye, Yitao Wang, Chuanbin Wu, Ram I Mahato

Research output: Contribution to journalReview article

Abstract

Active ingredients from Chinese medicine (AIFCM) are emerging as a class of anticancer agents for treating hepatocellular carcinoma (HCC). AIFCM have unique advantages over traditional chemotherapeutic drugs, such as their multi-target, multi-level, and coordinated intervention effects against HCC. Recent researches demonstrated their potentials in inhibiting HCC initiation, cell proliferation, angiogenesis, and metastasis. With the advantages of nano-carriers including better bioavailability, significant features of passive or active targeting and stimulus-responsive drug release. Formulation of AIFCM and nano-carriers shows great potential in promoting anti-HCC therapeutic development. Here, we critically assess nano-carriers for delivery and targeting of AIFCM for HCC therapy. First, we offer an overview of major pathogenic factors to induce HCC, including virus infection, alcoholic liver disease, mycotoxin, obesity, and type 2 diabetes. Second, the mechanisms of AIFCM for HCC therapy comprising gene regulation and transduction of different molecular pathways are discussed. Third, significant achievements of AIFCM-encapsulated nano-carriers and AIFCM-modified nano-carriers against HCC are presented. Finally, we provide concluding remarks and future perspectives of AIFCM for HCC therapy, hoping to offer some insight on how to improve AIFCM-based HCC therapy.

Original languageEnglish (US)
Pages (from-to)66-87
Number of pages22
JournalMaterials Today
Volume25
DOIs
StatePublished - May 2019

Fingerprint

medicine
ingredients
Medicine
therapy
delivery
cancer
drugs
obesity
angiogenesis
bioavailability
Mycotoxins
Bioelectric potentials
Cell proliferation
Medical problems
gene expression
Viruses
Gene expression
viruses
metastasis
infectious diseases

ASJC Scopus subject areas

  • Materials Science(all)
  • Condensed Matter Physics
  • Mechanics of Materials
  • Mechanical Engineering

Cite this

Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy. / Chen, Meiwan; Zhou, Xingzhi; Chen, Ruie; Wang, Junlin; Ye, Richard D.; Wang, Yitao; Wu, Chuanbin; Mahato, Ram I.

In: Materials Today, Vol. 25, 05.2019, p. 66-87.

Research output: Contribution to journalReview article

Chen, Meiwan ; Zhou, Xingzhi ; Chen, Ruie ; Wang, Junlin ; Ye, Richard D. ; Wang, Yitao ; Wu, Chuanbin ; Mahato, Ram I. / Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy. In: Materials Today. 2019 ; Vol. 25. pp. 66-87.
@article{b8f0837eb7924cb0a1df8081ed3afeff,
title = "Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy",
abstract = "Active ingredients from Chinese medicine (AIFCM) are emerging as a class of anticancer agents for treating hepatocellular carcinoma (HCC). AIFCM have unique advantages over traditional chemotherapeutic drugs, such as their multi-target, multi-level, and coordinated intervention effects against HCC. Recent researches demonstrated their potentials in inhibiting HCC initiation, cell proliferation, angiogenesis, and metastasis. With the advantages of nano-carriers including better bioavailability, significant features of passive or active targeting and stimulus-responsive drug release. Formulation of AIFCM and nano-carriers shows great potential in promoting anti-HCC therapeutic development. Here, we critically assess nano-carriers for delivery and targeting of AIFCM for HCC therapy. First, we offer an overview of major pathogenic factors to induce HCC, including virus infection, alcoholic liver disease, mycotoxin, obesity, and type 2 diabetes. Second, the mechanisms of AIFCM for HCC therapy comprising gene regulation and transduction of different molecular pathways are discussed. Third, significant achievements of AIFCM-encapsulated nano-carriers and AIFCM-modified nano-carriers against HCC are presented. Finally, we provide concluding remarks and future perspectives of AIFCM for HCC therapy, hoping to offer some insight on how to improve AIFCM-based HCC therapy.",
author = "Meiwan Chen and Xingzhi Zhou and Ruie Chen and Junlin Wang and Ye, {Richard D.} and Yitao Wang and Chuanbin Wu and Mahato, {Ram I}",
year = "2019",
month = "5",
doi = "10.1016/j.mattod.2018.10.040",
language = "English (US)",
volume = "25",
pages = "66--87",
journal = "Materials Today",
issn = "1369-7021",
publisher = "Elsevier",

}

TY - JOUR

T1 - Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy

AU - Chen, Meiwan

AU - Zhou, Xingzhi

AU - Chen, Ruie

AU - Wang, Junlin

AU - Ye, Richard D.

AU - Wang, Yitao

AU - Wu, Chuanbin

AU - Mahato, Ram I

PY - 2019/5

Y1 - 2019/5

N2 - Active ingredients from Chinese medicine (AIFCM) are emerging as a class of anticancer agents for treating hepatocellular carcinoma (HCC). AIFCM have unique advantages over traditional chemotherapeutic drugs, such as their multi-target, multi-level, and coordinated intervention effects against HCC. Recent researches demonstrated their potentials in inhibiting HCC initiation, cell proliferation, angiogenesis, and metastasis. With the advantages of nano-carriers including better bioavailability, significant features of passive or active targeting and stimulus-responsive drug release. Formulation of AIFCM and nano-carriers shows great potential in promoting anti-HCC therapeutic development. Here, we critically assess nano-carriers for delivery and targeting of AIFCM for HCC therapy. First, we offer an overview of major pathogenic factors to induce HCC, including virus infection, alcoholic liver disease, mycotoxin, obesity, and type 2 diabetes. Second, the mechanisms of AIFCM for HCC therapy comprising gene regulation and transduction of different molecular pathways are discussed. Third, significant achievements of AIFCM-encapsulated nano-carriers and AIFCM-modified nano-carriers against HCC are presented. Finally, we provide concluding remarks and future perspectives of AIFCM for HCC therapy, hoping to offer some insight on how to improve AIFCM-based HCC therapy.

AB - Active ingredients from Chinese medicine (AIFCM) are emerging as a class of anticancer agents for treating hepatocellular carcinoma (HCC). AIFCM have unique advantages over traditional chemotherapeutic drugs, such as their multi-target, multi-level, and coordinated intervention effects against HCC. Recent researches demonstrated their potentials in inhibiting HCC initiation, cell proliferation, angiogenesis, and metastasis. With the advantages of nano-carriers including better bioavailability, significant features of passive or active targeting and stimulus-responsive drug release. Formulation of AIFCM and nano-carriers shows great potential in promoting anti-HCC therapeutic development. Here, we critically assess nano-carriers for delivery and targeting of AIFCM for HCC therapy. First, we offer an overview of major pathogenic factors to induce HCC, including virus infection, alcoholic liver disease, mycotoxin, obesity, and type 2 diabetes. Second, the mechanisms of AIFCM for HCC therapy comprising gene regulation and transduction of different molecular pathways are discussed. Third, significant achievements of AIFCM-encapsulated nano-carriers and AIFCM-modified nano-carriers against HCC are presented. Finally, we provide concluding remarks and future perspectives of AIFCM for HCC therapy, hoping to offer some insight on how to improve AIFCM-based HCC therapy.

UR - http://www.scopus.com/inward/record.url?scp=85058823157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058823157&partnerID=8YFLogxK

U2 - 10.1016/j.mattod.2018.10.040

DO - 10.1016/j.mattod.2018.10.040

M3 - Review article

AN - SCOPUS:85058823157

VL - 25

SP - 66

EP - 87

JO - Materials Today

JF - Materials Today

SN - 1369-7021

ER -